Leanne Marsay
Overview
Explore the profile of Leanne Marsay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
Dold C, Marsay L, Wang N, Silva-Reyes L, Clutterbuck E, Paterson G, et al.
Sci Transl Med
. 2023 Jun;
15(701):eade3901.
PMID: 37343082
Adenoviral-vectored vaccines are licensed for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus, but, for bacterial proteins, expression in a eukaryotic cell may affect the antigen's...
2.
Rennie K, Witham M, Bradley P, Clegg A, Connolly S, Hancock H, et al.
BMJ Open
. 2022 Jul;
12(7):e061823.
PMID: 35851031
Introduction: Skeletal muscle dysfunction is central to both sarcopenia and physical frailty, which are associated with a wide range of adverse outcomes including falls and fractures, longer hospital stays, dependency...
3.
Chang C, Awanye A, Marsay L, Dold C, Pollard A, Rollier C, et al.
Vaccine
. 2022 May;
40(28):3835-3842.
PMID: 35610106
Meningococcal meningitis is a rare but serious condition affecting mainly children and young adults. Outer membrane vesicles (OMV) from Neisseria meningitidis have been used successfully as vaccines against the disease,...
4.
Marsay L, Dold C, Paterson G, Yamaguchi Y, Derrick J, Chan H, et al.
J Infect
. 2022 Mar;
84(5):658-667.
PMID: 35245584
Objective: Adenoviral vectored vaccines, with the appropriate gene insert, induce cellular and antibody responses against viruses, parasites and intracellular pathogens such as Mycobacterium tuberculosis. Here we explored their capacity to...
5.
Rollier C, Dold C, Marsay L, Linder A, Green C, Sadarangani M, et al.
mSphere
. 2022 Jan;
7(1):e0067421.
PMID: 35080470
Neisseria meningitidis outer membrane vesicle (OMV) vaccines are safe and provide strain-specific protection against invasive meningococcal disease (IMD) primarily by inducing serum bactericidal antibodies against the outer membrane proteins (OMP)....
6.
Maier R, Kasim A, Zacharias J, Vale L, Graham R, Walker A, et al.
BMJ Open
. 2021 Apr;
11(4):e047676.
PMID: 33853807
Introduction: Numbers of patients undergoing mitral valve repair (MVr) surgery for severe mitral regurgitation have grown and will continue to rise. MVr is routinely performed via median sternotomy; however, there...
7.
Maier R, Bawamia B, Bennaceur K, Dunn S, Marsay L, Amoah R, et al.
JMIR Res Protoc
. 2020 Sep;
9(9):e19456.
PMID: 32965237
Background: Inflammation plays a key role in the pathophysiology of coronary heart disease (CHD) and its acute manifestation, acute coronary syndrome (ACS). Aging is associated with a decline of the...
8.
Muller J, Tanner R, Matsumiya M, Snowden M, Landry B, Satti I, et al.
JCI Insight
. 2019 Nov;
4(23).
PMID: 31697647
Immune activation is associated with increased risk of tuberculosis (TB) disease in infants. We performed a case-control analysis to identify drivers of immune activation and disease risk. Among 49 infants...
9.
Awanye A, Chang C, Wheeler J, Chan H, Marsay L, Dold C, et al.
Sci Rep
. 2019 May;
9(1):6843.
PMID: 31048732
Outer membrane vesicle (OMV)- based vaccines have been used to provide strain-specific protection against capsular group B Neisseria meningitidis infections, but the full breadth of the immune response against the...
10.
Weissmueller N, Marsay L, Schiffter H, Carlisle R, Rollier C, Prudhomme R, et al.
PLoS One
. 2017 Aug;
12(8):e0183427.
PMID: 28837693
Powder-injectors use gas propulsion to deposit lyophilised drug or vaccine particles in the epidermal and sub epidermal layers of the skin. We prepared dry-powder (Tg = 45.2 ± 0.5°C) microparticles...